 |
|
|
| |
Incidence and prevalence of recorded non-alcoholic fatty liver disease in four European primary care databases covering 21.9 million adults
|
| |
| |
CROI: FATTY LIVER DISEASE: A GROWING CONCERN - - (04/12/17) a plenary talk by noted fatty liver expert Rohit Loomba from UCSD, Higher prevalence in HIV+ vs general population by 30-40%
CROI: Changes in Liver Fibrosis and Steatosis in HIV Mono-Infected patients over 24 months - 50% have fatty liver at average age of 46 - (03/28/17)
CROI: LIVER STEATOSIS AND FIBROSIS IN AT-RISK EUROPEAN HIV-MONOINFECTED PATIENTS - 64% with steatosis among those who had elevated LFTs and/or metabolic syndrome and/or lipodystrophy - (03/28/17) Of 140 patients eligible for liver biopsy, the procedure was performed in 50 (35%). Histological analysis was available for 49 patients and found NAFLD in 76% and NASH in 47%.
CROI: Hyperbilirubinemia prevents cardiovascular disease for HIV+ and HIV-individuals - (02/20/17)
Reported by Jules Levin
EASL 2017 April 19-23 Amsterdam Netherlands
Myriam Alexander1, A. Katrina Loomis2, Jolyon Fairburn-Beech3, Johan van der Lei4, Talita Duarte-Salles5, David Ansell6, Alessandro Pasqua7, Peter Rijnbeek4, Paul Avillach8, Stuart Kendrick9, Dawn Waterworth10, Naveed Sattar11, William Alazawi* 12
1Real World Data, GlaxoSmithKline, Uxbridge, United Kingdom, 2Genome Sciences and Technologies, Pfizer, Groton, CT United States, 3Real World Data and Analytics, GlaxoSmithKline, Uxbridge, United Kingdom, 4Erasmus Medical Centre, Rotterdam, The Netherlands, 5Institut Universitari d'Investigacio en Atencio Primāria Jordi Gol (IDIAP Jordi Gol), Barcelona, Spain, 6Quintile IMS, London, United Kingdom, 7Genomedics, Firenze, Italy, 8Harvard Medical School, Harvard, United States, 9GlaxoSmithKline, Stevenage, United Kingdom, 10Genetics, GlaxoSmithKline, King of Prussia PA, United States, 11BHF Glasgow Cardiovascular Research Centre, Glasgow, 12Queen Mary University, London, United Kingdom
|
| |
|
|
|
|
|
